Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01902823
Other study ID # 11-86E
Secondary ID OS11336A545000NU
Status Terminated
Phase Phase 2/Phase 3
First received
Last updated
Start date November 2011
Est. completion date May 2012

Study information

Verified date November 2015
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There is widespread anecdotal evidence that Cancer Nurse Navigators (CNNs) are highly valued by cancer patients, but no studies have evaluated the effects of CNNs on important patient-reported outcomes or indicators of quality of care. This study has two aims:

1. To assess the feasibility of studying the impact of Aurora CNN Program.

2. To pilot test the effects of CNN services on patient-reported outcomes and indicators of quality of care.


Recruitment information / eligibility

Status Terminated
Enrollment 16
Est. completion date May 2012
Est. primary completion date May 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Adult (18 years of age or older)

2. Treated at Aurora St. Luke's or West Allis Medical Center

3. New or recurrent dx of lung, prostate, colorectal or breast cancer -

Exclusion Criteria:

1. Previously received CNN services at an Aurora treatment facility

2. Unable to read/write in English

3. Living in a nursing home/long term care facility

4. Not capable of completing study questionnaires -

Study Design


Intervention

Behavioral:
Services from a Nurse Navigator
Services from a Nurse Navigator

Locations

Country Name City State
United States Aurora St. Luke's Hospital Milwaukee Wisconsin
United States Aurora West Allis West Allis Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
University of Wisconsin, Madison Aurora Health Care

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Satisfaction with Care Change from baseline, to 3 months to 6 months
Secondary ED/Urgent care visits Baseline, 3 months, 6 months
Secondary Quality of Life The Functional Assessment Cancer Therapy - General (FACT-G) assesses quality of life. Baseline, 3 months, 6 months
Secondary Distressed mood The National Comprehensive Cancer Network Distress Thermometer assesses level of distress. Baseline, 3 months, 6 months
Secondary Symptom Distress The Memorial Symptom Assessment Scale measures 32 common physical and psychological cancer-related symptoms. Baseline, 3 months, 6 months
Secondary The Inventory of Recent Life Experiences for Cancer Patients This instrument measures 30 cancer-related irritants (hassles) commonly experienced by persons with cancer. Baseline, 3 months, 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A